Literature DB >> 28225987

Can FIB4 and NAFLD fibrosis scores help endocrinologists refer patients with non-alcoholic fat liver disease to a hepatologist?

Rodrigo Bremer Nones1, Cláudia Pontes Ivantes1, Maria Lucia Alves Pedroso2.   

Abstract

OBJECTIVE: The objective of this study is to evaluate the performance of mathematical models used in non-invasive diagnosis of liver fibrosis in nonalcoholic fatty liver disease (NAFLD) patients to determine when the patient needs to be referred to a hepatologist. SUBJECTS AND METHODS: Patients referred by endocrinologists to the liver outpatient departments in two hospitals in Curitiba, Brazil, over a 72-month period were analyzed. The results calculated using the APRI, FIB 4, FORNS and NAFLD Fibrosis Score non-invasive liver fibrosis assessment models were analyzed and compared with histological staging of this population.
RESULTS: Sixty-seven patients with NAFLD were analyzed. Forty-two of them (62.68%) were female, mean age was 54.76 (±9.63) years, mean body mass index 31.42 (±5.64) and 59 (88.05%) of the 67 cases had glucose intolerance or diabetes. A diagnosis of steatohepatitis was made in 45 (76.27%) of the 59 biopsied patients, and advanced liver fibrosis (stages 3 and 4) was diagnosed in 18 (26.86%) of the 67 patients in the study population. The FIB 4 and NAFLD Fibrosis Score models had a high negative predictive value (93.48% and 93.61%, respectively) in patients with severe liver fibrosis (stages 3 and 4).
CONCLUSION: In conclusion, use of the FIB 4 and NAFLD Fibrosis Score models in NAFLD patients allows a diagnosis of severe liver disease to be excluded.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28225987     DOI: 10.1590/2359-3997000000233

Source DB:  PubMed          Journal:  Arch Endocrinol Metab        ISSN: 2359-3997            Impact factor:   2.309


  6 in total

1.  Development of liver surface nodularity quantification program and its clinical application in nonalcoholic fatty liver disease.

Authors:  Tae-Hoon Kim; Ji Eon Kim; Jong-Hyun Ryu; Chang-Won Jeong
Journal:  Sci Rep       Date:  2019-07-10       Impact factor: 4.379

Review 2.  Overview of the Pathogenesis, Genetic, and Non-Invasive Clinical, Biochemical, and Scoring Methods in the Assessment of NAFLD.

Authors:  Viera Kupčová; Michaela Fedelešová; Jozef Bulas; Petra Kozmonová; Ladislav Turecký
Journal:  Int J Environ Res Public Health       Date:  2019-09-24       Impact factor: 3.390

3.  Patients with type 2 diabetes and elevated fibrosis-4 are under-referred to hepatology and have unrecognized hepatic decompensation.

Authors:  Winston Dunn; Xing Song; Devin Koestler; Kristine Grdinovac; Eyad Al-Hihi; John Chen; Ryan Taylor; Jessica Wilson; Steven A Weinman
Journal:  J Gastroenterol Hepatol       Date:  2022-06-15       Impact factor: 4.369

4.  Efficacy of canagliflozin against nonalcoholic fatty liver disease: a prospective cohort study.

Authors:  Toshio Itani; Tomoaki Ishihara
Journal:  Obes Sci Pract       Date:  2018-08-22

5.  One-year weight management lowers lipopolysaccharide-binding protein and its implication in metainflammation and liver fibrosis.

Authors:  Hsiao-Ching Nien; Jin-Chuan Sheu; Yu-Chiao Chi; Chi-Ling Chen; Jia-Horng Kao; Wei-Shiung Yang
Journal:  PLoS One       Date:  2018-11-20       Impact factor: 3.240

6.  OBESITY AND SEVERE STEATOSIS: THE IMPORTANCE OF BIOCHEMICAL EXAMS AND SCORES.

Authors:  Miller Barreto de Brito E Silva; Francisco Tustumi; Anna Carolina Batista Dantas; Barbara Cristina Jardim Miranda; Denis Pajecki; Roberto DE-Cleva; Marco Aurelio Santo; Sergio Carlos Nahas
Journal:  Arq Bras Cir Dig       Date:  2022-01-31
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.